Cheryl L De Hoyos
Overview
Explore the profile of Cheryl L De Hoyos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liang X, Nichols J, De Hoyos C, Crooke S
Nucleic Acids Res
. 2020 Sep;
48(17):9840-9858.
PMID: 32870273
Antisense oligonucleotide (ASO) drugs that trigger RNase H1 cleavage of target RNAs have been developed to treat various diseases. Basic pharmacological principles suggest that the development of tolerance is a...
2.
Ostergaard M, De Hoyos C, Wan W, Shen W, Low A, Berdeja A, et al.
Nucleic Acids Res
. 2020 Jan;
48(4):1691-1700.
PMID: 31980820
Therapeutic oligonucleotides are often modified using the phosphorothioate (PS) backbone modification which enhances stability from nuclease mediated degradation. However, substituting oxygen in the phosphodiester backbone with sulfur introduce chirality into...
3.
Liang X, Sun H, Hsu C, Nichols J, Vickers T, De Hoyos C, et al.
Nucleic Acids Res
. 2019 Dec;
48(3):1372-1391.
PMID: 31840180
Release of phosphorothioate antisense oligonucleotides (PS-ASOs) from late endosomes (LEs) is a rate-limiting step and a poorly defined process for productive intracellular ASO drug delivery. Here, we examined the role...
4.
Shen W, De Hoyos C, Migawa M, Vickers T, Sun H, Low A, et al.
Nat Biotechnol
. 2019 May;
37(6):640-650.
PMID: 31036929
The molecular mechanisms of toxicity of chemically modified phosphorothioate antisense oligonucleotides (PS-ASOs) are not fully understood. Here, we report that toxic gapmer PS-ASOs containing modifications such as constrained ethyl (cEt),...
5.
Migawa M, Shen W, Wan W, Vasquez G, Oestergaard M, Low A, et al.
Nucleic Acids Res
. 2019 Apr;
47(11):5465-5479.
PMID: 31034558
Phosphorothioate-modified antisense oligonucleotides (PS-ASOs) interact with a host of plasma, cell-surface and intracellular proteins which govern their therapeutic properties. Given the importance of PS backbone for interaction with proteins, we...
6.
Shen W, De Hoyos C, Sun H, Vickers T, Liang X, Crooke S
Nucleic Acids Res
. 2018 Feb;
46(5):2204-2217.
PMID: 29390093
We reported previously that a 2' fluoro-modified (2' F) phosphorothioate (PS) antisense oligonucleotides (ASOs) with 5-10-5 gapmer configuration interacted with proteins from Drosophila behavior/human splicing (DBHS) family with higher affinity...
7.
Shen W, Sun H, De Hoyos C, Bailey J, Liang X, Crooke S
Nucleic Acids Res
. 2017 Oct;
45(18):10672-10692.
PMID: 28977560
An R-loop is a DNA:RNA hybrid formed during transcription when a DNA duplex is invaded by a nascent RNA transcript. R-loops accumulate in nucleoli during RNA polymerase I (RNAP I)...
8.
Shen W, Liang X, Sun H, De Hoyos C, Crooke S
PLoS One
. 2017 Mar;
12(3):e0173494.
PMID: 28288210
Altered expression of NEAT1, the architectural long non-coding RNA (lncRNA) of nuclear paraspeckles, has been reported during tumorigenesis, as well as under various cellular stress conditions. Here we report that...
9.
Lima W, De Hoyos C, Liang X, Crooke S
Nucleic Acids Res
. 2016 Feb;
44(7):3351-63.
PMID: 26843429
DNA-based antisense oligonucleotides (ASOs) elicit cleavage of the targeted RNA by the endoribonuclease RNase H1, whereas siRNAs mediate cleavage through the RNAi pathway. To determine the fates of the cleaved...